Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults or Adults Recommencing ART.

NCT01258439 is registered in ClinicalTrials.gov with St Vincent's Hospital, Sydney as lead sponsor.

NCT NCT01258439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01258439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults or Adults Recommencing ART.
Lead sponsor
St Vincent's Hospital, Sydney
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2010
Completion date
July 31, 2014
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, hiv